CHE Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
690.9M
+2.6%
673.3M
+2.4%
657.5M
+2.8%
639.3M
+2.3%
624.9M
Cost of Revenue
458.0M
+1.4%
451.8M
+2.3%
441.7M
+6.7%
414.2M
-2.6%
425.1M
Gross Profit
233.0M
+5.2%
221.5M
+2.6%
215.8M
-4.2%
225.2M
+12.7%
199.8M
Operating Expenses
136.5M
+3.2%
132.3M
+0.8%
131.2M
+5.4%
124.5M
-0.4%
125.0M
R&D
0
0
0
0
0
SG&A
111.5M
-3.2%
115.2M
+0.8%
114.3M
+8.4%
105.5M
-0.3%
105.8M
Operating Income
96.4M
+8.1%
89.2M
+5.5%
84.6M
-16.0%
100.7M
+34.7%
74.8M
EBITDA
113.8M
+7.2%
106.2M
+4.7%
101.5M
-13.3%
117.0M
+28.6%
91.0M
Net Income
71.6M
+5.8%
67.7M
+2.1%
66.3M
-13.6%
76.8M
+19.5%
64.2M
EPS (Basic)
$5.49
+6.8%
$5.14
+6.0%
$4.85
-11.7%
$5.49
+23.1%
$4.46
EPS (Diluted)
$5.45
+6.2%
$5.13
+6.0%
$4.84
-12.0%
$5.50
+23.3%
$4.46
Shares (Diluted)
13.1M
-0.5%
13.2M
-3.6%
13.7M
-2.0%
14.0M
-3.1%
14.4M
Chemed (CHE) — Financials